On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

被引：0
作者：
Chang Gon Kim
Min Hwan Kim
Jee Hung Kim
Seul-Gi Kim
Gun Min Kim
Tae Yeong Kim
Won-Ji Ryu
Jee Ye Kim
Hyung Seok Park
Seho Park
Young Up Cho
Byeong Woo Park
Seung Il Kim
Joon Jeong
Joohyuk Sohn
机构：
[1] Yonsei University College of Medicine,Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center
[2] Yonsei University College of Medicine,Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital
[3] Yonsei University College of Medicine,Institute for Breast Cancer Precision Medicine
[4] Yonsei University College of Medicine,Avison Biomedical Research Center
[5] Yonsei University College of Medicine,Division of Breast Surgery, Department of Surgery, Yonsei Cancer Center
[6] Yonsei University College of Medicine,Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital
来源：
Breast Cancer Research | / 25卷
关键词：
Advanced breast cancer; CDK4/6 inhibitor; Neutrophil-to-lymphocyte ratio; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 437 条
  • [1] Yu Q(2006)Requirement for CDK4 kinase function in breast cancer Cancer Cell 9 23-32
  • [2] Sicinska E(2012)The requirement for cyclin D function in tumor maintenance Cancer Cell 22 438-451
  • [3] Geng Y(2016)Treating cancer with selective CDK4/6 inhibitors Nat Rev Clin Oncol 13 417-430
  • [4] Ahnström M(2016)Targeting CDK4/6 in patients with cancer Cancer Treat Rev 45 129-138
  • [5] Zagozdzon A(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-35
  • [6] Kong Y(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 375 1738-1748
  • [7] Gardner H(2017)MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol Off J Am Soc Clin Oncol 35 2875-2884
  • [8] Kiyokawa H(2019)Overall survival with ribociclib plus endocrine therapy in breast cancer N Engl J Med 381 307-316
  • [9] Harris LN(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1936
  • [10] Stål O(2015)Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 373 209-219
12345678910